Abstract
The term tachycardia-induced cardiomyopathy refers to a systolic ventricular dysfunction and dilatation with clinical presentation of heart failure in patients with chronic tachyarrhythmia. Characteristic feature of this disease is partial or full reversibility of functional and structural changes upon the restoration of the heart rhythm.
Therefore, besides the standard treatment of heart failure is the correction of tachyarrhythmia the crucial point in the successful treatment of tachycardia induced cardiomyopathy, since the tachyarrhythmia is the main pathophysiological factor in the origin and development of the disease.